^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    anti-CD19-CAR

    i
    Other names: anti-CD19-CAR, anti-CD19 chimeric antigen receptor T cell therapy, CD19 Chimeric Antigen Receptor (CAR) redirected autologous T-cells
    Associations

    News

    Trials
    Company:
    Kecellitics Biotech
    Drug class:
    CD19-targeted CAR-T immunotherapy
    Related drugs:
    Associations

    News

    Trials
    2years
    Immunotherapy With CD19 CAR T-cells for B-Cell Leukemia (clinicaltrials.gov)
    P1, N=100, Not yet recruiting, Kecellitics Biotech Company Ltd | Trial completion date: Aug 2022 --> Aug 2024 | Trial primary completion date: Aug 2021 --> Aug 2023
    Trial completion date • Trial primary completion date • CAR T-Cell Therapy
    |
    CD19 (CD19 Molecule)
    |
    CD19 expression
    |
    anti-CD19-CAR